Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmacological Research

• Publication date

  2016-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.phrs.2016.08.002PMID 27498158
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2016

  2016cited by this paper
• Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.

  2016cited by this paper
• NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

  2016cited by this paper
• The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients

  2016cited by this paper
• Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.

  2015cited by this paper
• Interleukin polymorphisms associated with overall survival, disease‐free survival, and recurrence in non‐small cell lung cancer patients

  2015cited by this paper
• Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.

  2015cited by this paper
• Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcomes of patients with advanced non-small cell lung cancer.

  2015cited by this paper
• ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

  2015cited by this paper
• IL1B gene polymorphisms, age and the risk of non-small cell lung cancer in a Chinese population.

  2015cited by this paper
• IL-6 polymorphism in non-small cell lung cancer: a prognostic value?

  2015cited by this paper
• Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients

  2015cited by this paper
• Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.

  2014cited by this paper
• Inherited Variation in the ATP-Binding Cassette Transporter ABCB1 and Survival after Chemotherapy for Stage III–IV Lung Cancer

  2014cited by this paper
• Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations

  2014cited by this paper
• Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum‐based chemotherapy in advanced nonsmall‐cell lung cancer patients

  2014cited by this paper
• Abstract 5554: Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small cell lung cancer

  2014cited by this paper
• Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy

  2014cited by this paper
• Pharmacogenetics role in the safety of acenocoumarol therapy

  2014cited by this paper
• Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.

  2014cited by this paper
• Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

  2014cited by this paper
• Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer.

  2014cited by this paper
• Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy

  2013cited by this paper
• Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with Platinum-Based Chemotherapy: A Three-Dimensional (3-D), Polyacrylamide Gel-Based DNA Microarray Method

  2013cited by this paper
• Chemotherapy Plus Best Supportive Care versus Best Supportive Care in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

  2013cited by this paper
• Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer

  2013cited by this paper
• Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer

  2012cited by this paper
• Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy

  2012cited by this paper
• Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

  2012cited by this paper
• Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.

  2012cited by this paper
• Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.

  2012cited by this paper
• Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients

  2012cited by this paper
• Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy

  2012cited by this paper
• Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role.

  2012cited by this paper
• Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.

  2011cited by this paper
• Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer.

  2011cited by this paper
• Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.

  2011cited by this paper
• Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.

  2011cited by this paper
• Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation

  2011cited by this paper
• Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.

  2011cited by this paper
• Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

  2011cited by this paper
• Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.

  2011cited by this paper
• Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study

  2010cited by this paper
• Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

  2009cited by this paper
• Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

  2009cited by this paper
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

  2009cited by this paper
• Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

  2009cited by this paper
• Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

  2008cited by this paper
• Lung cancer.

  2008cited by this paper
• Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients

  2008cited by this paper
• PLINK: a tool set for whole-genome association and population-based linkage analyses.

  2007cited by this paper
• Prognostic significance of folate metabolism polymorphisms for lung cancer

  2007cited by this paper
• A cytokine-mediated link between innate immunity, inflammation, and cancer.

  2007cited by this paper
• An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy.

  2006cited by this paper
• Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients

  2005cited by this paper
• Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy

  2005cited by this paper
• Cytokines in cancer pathogenesis and cancer therapy

  2004cited by this paper
• Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

  2004cited by this paper
• Tumour-educated macrophages promote tumour progression and metastasis

  2004cited by this paper
• Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review.

  2004cited by this paper
• The p53-Mdm2 module and the ubiquitin system.

  2003cited by this paper
• MDR1 genotype-related pharmacokinetics and pharmacodynamics.

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Inflammation and cancer

  2002cited by this paper
• The p53 functional circuit.

  2001cited by this paper
• Recognition of cisplatin adducts by cellular proteins.

  2001cited by this paper
• Molecular mechanisms involved in cisplatin cytotoxicity

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.

  1998cited by this paper
• Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders.

  1996cited by this paper
• Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.

  1996cited by this paper
• A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

  1995cited by this paper
• DNA repair in humans.

  1995cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper
• Minireview. The nephrotoxicity of cisplatin.

  1983cited by this paper
• The nephrotoxicity of cisplatin

  1983cited by this paper
• Platinum nephrotoxicity.

  1978cited by this paper

• Targeting shared mechanisms of cisplatin resistance and metastasis in lung cancer for novel therapeutic strategies

  2026cites this paper
• Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies

  2025cites this paper
• ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer

  2024cites this paper
• Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy.

  2024cites this paper
• To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment

  2024cites this paper
• IL16 and factor V gene variations are associated with asparaginase-related thrombosis in childhood acute lymphoblastic leukemia patients.

  2023cites this paper
• Pharmacogenetic markers of chemotherapy toxicity in gastrointestinal tumors: a preliminary analysis

  2021cites this paper
• Systematic review and meta-analysis of the predictive power of MTHFR polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients

  2021cites this paper
• MTHFR polymorphism as a predictive biomarker for gastrointestinal and hematological toxicity in North Indian adenocarcinoma patients

  2021cites this paper
• The influence of genetic polymorphisms on the toxicity of platinum-based chemotherapy in the treatment of non-small cell lung cancer

  2021influential citation
• ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine

  2021cites this paper
• ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers

  2020cites this paper
• Genetic Polymorphisms and Platinum-Based Chemotherapy-Induced Toxicities in Patients With Lung Cancer: A Systematic Review and Meta-Analysis

  2020cites this paper
• Deoxyshikonin inhibits cisplatin resistance of non–small‐cell lung cancer cells by repressing Akt‐mediated ABCB1 expression and function

  2020cites this paper
• Application of pharmacogenetics in oncology

  2020cites this paper
• Interaction between common variants of MDM2 and PPP1R13L and CD3EAP and TP53 SNPs in relation to lung cancer risk among Chinese

  2020cites this paper
• Impact of genetic factors on platinum-induced gastrointestinal toxicity.

  2020cites this paper
• Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non‐small cell lung cancer patients

  2019cites this paper
• Platinum, palladium, and rhodium in airborne particulate matter

  2019cites this paper
• Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

  2019cites this paper
• Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers

  2019cites this paper
• Role of epigenetic mechanisms in cisplatin-induced toxicity.

  2019cites this paper
• Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum‐based chemoradiotherapy treatment

  2019influential citation
• Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients

  2019cites this paper
• Association between IL1B gene and cervical cancer susceptibility in Chinese Uygur Population: A Case–Control study

  2019cites this paper
• ABCB1 Variation Affects Myelosuppression, Progression‐free Survival and Overall Survival in Paclitaxel/Carboplatin‐treated Ovarian Cancer Patients

  2018cites this paper
• An ERCC4 regulatory variant predicts grade‐3 or ‐4 toxicities in patients with advanced non‐small cell lung cancer treated by platinum‐based therapy

  2018cites this paper
• ABCB 1 variation affects myelosuppression , progression-free 1 survival , and overall survival in paclitaxel / carboplatin-treated 2 ovarian cancer patients 3

  2018cites this paper
• The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum‐based chemotherapy

  2017cites this paper
• Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer.

  2017cites this paper
• Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.

  2017cites this paper
• Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use

  2016cites this paper